Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10282928 | 0.91 | ADM2 (0.59) | ADM2CALCB | |
| SCHEMBL10282929 | 0.86 | ADM2 (0.55) | ADM2CALCB | |
| SCHEMBL14069415 | 0.80 | ADM2 (0.55) | ADM2CALCB | |
| SCHEMBL10282931 | 0.78 | ADM2 (0.56) | ADM2CALCB | |
| SCHEMBL10282930 | 0.77 | ADM2 (0.57) | ADM2CALCB | |
| SCHEMBL14069221 | 0.77 | ADM2 (0.50) | ADM2CALCB | |
| SCHEMBL10282889 | 0.76 | ADM2 (0.53) | ADM2CALCB | |
| SCHEMBL10282890 | 0.75 | ADM2 (0.53) | ADM2CALCB | |
| SCHEMBL23257434 | 0.74 | ADM2 (0.83) | ADM2CALCB | |
| SCHEMBL29813740 | 0.74 | ADM2 (0.83) | ADM2CALCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148390-B2 | Monocyclic anilide spirolactam CGRP receptor antagonists | Merck, Sharp & Dohme, Corp. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20100152216-A1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152216-A1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | BDKRB1, BDKRB2, CALCRL | ADM2 87/4885CALCB 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.